STAT
DECEMBER 21, 2023
Odds are, you’ve gotten at least one of the unnerving letters in your mailbox this year: “We’re writing to inform you of a cybersecurity incident,” it might start. It’s the standard notice many health care organizations are required to provide when your protected health information gets exposed — and in 2023, data leaks, hacks, and mishandling led more of them to be delivered than ever before.
PharmaVoice
DECEMBER 21, 2023
Closer scrutiny of pharma deals has made the M&A landscape trickier as a new approach seeks to expand the competitive arena.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 21, 2023
The past year has brought huge changes in medicine and science — from innovations like the first curative treatment for sickle cell to legislative restrictions on abortion access. But at the center of all these stories are the people they impact: scientists, doctors, patients, and families. As we look back at 2023 in photographs, the faces of so many stand out: investors and researchers moving their industries forward, a man working to escape the cycle of addiction, a physi
Pharma Times
DECEMBER 21, 2023
The condition affects around 270,935 people in England and 16,090 people in Wales - News - PharmaTimes
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
DECEMBER 21, 2023
WASHINGTON — Sometime next year drug and medical device companies will have to tell the Food and Drug Administration how they plan to include people of color in clinical trials. But planning isn’t the same as doing, the industry’s track record isn’t great, and it’s not clear whether the FDA will twist arms, experts told STAT.
Pharma Times
DECEMBER 21, 2023
The National Institute for Health and Care Excellence (NICE) has published final guidance announcing a five-year roll-out of a wearable technology for patients living with type 1 diabetes. The new hybrid closed loop systems have proven to be more effective in maintaining healthy blood glucose levels than standard care. The new guidance followed a review of a clinical trial and real-world evidence by the University of Warwick and Warwick Medical School, funded by the National Institute for Health
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharma Times
DECEMBER 21, 2023
Bowel cancer is currently the third most common type of cancer in England - News - PharmaTimes
STAT
DECEMBER 21, 2023
WASHINGTON — Medical marijuana companies sell medicine, just like pharmaceutical companies. But they’re not playing by the same rules — and that’s putting patients at risk. Several of the largest medical marijuana companies, like Trulieve, Curaleaf, and Verano, are advertising their products as treatments not just for muscle aches, but for major medical conditions like cancer and depression, without evidence to back up those claims.
Express Pharma
DECEMBER 21, 2023
On the financial details of the agreements, JB Pharma said it will pay USD 116 million (Rs 964 crore), excluding applicable taxes, stamp duty and working capital, for the trade marks licence agreement to Novartis Innovative Therapies AG, Switzerland JB Pharma on Tuesday said it has inked a trade mark licence agreement along with a promotion and distribution pact with Novartis for select ophthalmology brands entailing a total sum of Rs 1,089 crore.
STAT
DECEMBER 21, 2023
The Food and Drug Administration approved a novel medicine for a rare and devastating nerve disease Thursday, clearing a treatment that promises to be more convenient than available therapies. The drug, from partners AstraZeneca and Ionis Pharmaceuticals, is a monthly injection for a genetic disorder called ATTR-PN, in which a buildup of toxic bodily proteins progressively damages patients’ peripheral nerves.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
DECEMBER 21, 2023
An organisation representing the interests of patients with prostate cancer has published a manifesto ahead of the EU elections next year, calling for more screening for the disease in EU member states.
STAT
DECEMBER 21, 2023
Chronic disease is, by its very definition, omnipresent. But changes year to year have the potential to make certain conditions into flaming-red targets for researchers and drugmakers. This year was one for obesity, marked by new — and for the first time, highly effective — weight loss drugs that demonstrated other health benefits. But whether that wave of interest will persist into the new year, or transfer to some other condition — maybe some liver diseases that are
Pharma Times
DECEMBER 21, 2023
The NHS has announced the expansion of its home-testing kits for bowel cancer in an effort to detect signs of the disease and diagnose it earlier. The expansion of the NHS Bowel Cancer Screening Programme aligns with the health service’s aim of detecting cancers at an earlier stage when they are easier to treat. Currently the third most common type of cancer in England and responsible for almost 43,000 new cases in the UK every year, bowel cancer starts in the large bowel (colon) and the back pa
STAT
DECEMBER 21, 2023
What does it mean to a bad CEO? Can biotech endure another election year? And can you go to too many J.P. Morgan parties? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our last episode of 2023, so we look back on the biggest stories of the year, discuss the best and worst CEOs in the industry, and make some reasonably informed guesses on what 2024 has in store for the drug industry.
Express Pharma
DECEMBER 21, 2023
Zepbound is Eli Lilly ’s new glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist, approved by the FDA in November 2023, showing great promise compared to the other GLP-1R agonists on the market. However, the issue of rebound upon drug withdrawal remains an unmet need in the GLP-1R agonist space Eli Lilly recently published the results of a Phase III trial investigating the maintenance of Zepbound’s weight loss effects in overweight and obesity patients.
STAT
DECEMBER 21, 2023
Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter here. Good morning. Don’t miss Nicholas Florko’s jaw-dropping investigation into medical marijuana businesses marketing their products for cancer or depression with no regulatory oversight.
pharmaphorum
DECEMBER 21, 2023
Sanofi ends development of CEACAM5-targeting ADC tusamitamab ravtansine after it fails a phase 3 trial in non-small cell lung cancer (NSCLC)
STAT
DECEMBER 21, 2023
Good morning, everyone. Damian Garde here, filling in for Ed Silverman in a week customarily devoted to deciding just which tasks one can get away with putting off until next year. Here’s hoping you’re firmly on the downslope of doing actual work for the remainder of 2023. In the meantime, here are a few tidbits to start your day. And, as always, do let us know if you hear anything interesting out there.
European Pharmaceutical Review
DECEMBER 21, 2023
Piramal Pharma Solutions has officially opened new facilities at its antibody-drug conjugate (ADC) manufacturing facility in Grangemouth, Scotland. This expansion enhances the site’s capacity by 70-80 percent and will enable scale-up of commercial ADC manufacturing batches. “The global ADC market is growing strongly and so is the pipeline at Grangemouth, necessitating additional capacity to meet customer demand,” said Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions.
STAT
DECEMBER 21, 2023
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with news of an averted activist challenge, biotech on late-night TV, and the latest deal in oncology’s hottest space.
pharmaphorum
DECEMBER 21, 2023
NICE backs NHS use of digital COPD rehab programmes, myCOPD and SPACE for COPD, as an alternative to face-to-face consultations
European Pharmaceutical Review
DECEMBER 21, 2023
The UK’s National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance recommending Lynparza (olaparib) for use as combination therapy with abiraterone and prednisone or prednisolone, for untreated hormone-relapsed metastatic prostate cancer in adults who cannot have or do not want chemotherapy. This NICE recommendation is based on data from the PROpel Phase III clinical trial, which enrolled 700 patients globally.
Pharmaceutical Technology
DECEMBER 21, 2023
Genevoyager has announced the opening of contract development and manufacturing organisation facility to manufacture gene therapy products.
pharmaphorum
DECEMBER 21, 2023
Lilly partners with Fauna Bio in $494m deal to see if a hibernating squirrel's genomics could unlock new obesity drug targets.
Outsourcing Pharma
DECEMBER 21, 2023
The pharmaceutical industry in 2023 has seen many investments, partnerships, acquisitions and more. As the year ends, industry leaders give the biggest trends to look for in 2024, with artificial intelligence being a hot topic.
pharmaphorum
DECEMBER 21, 2023
Indivior has secured a $111 million BARDA supply contract in the US for its Opvee intranasal therapy for treating opioid overdose
The Pharmacist
DECEMBER 21, 2023
Pharmacy First will put community pharmacy ‘under the microscope’, according to Alastair Buxton, director of NHS Services for Community Pharmacy England (CPE). Mr Buxton was speaking in a recent CPE webinar – called Pharmacy First: Getting to know the service – to help pharmacists prepare ahead of the scheme’s scheduled launch on 31 January 2024. […] The post Pharmacists will be ‘under the microscope’ in delivering Pharmacy First appeared first on The Pharmacist.
pharmaphorum
DECEMBER 21, 2023
FDA issues a second complete response letter to MSD's gefapixant for chronic cough, giving GSK a chance to catch up with camlipixant
The Pharmacist
DECEMBER 21, 2023
The launch date for Pharmacy First of 31 January remains on track although contingency plans are being put in place in case it is pushed back, a Community Pharmacy England (CPE) webinar has revealed. Uncertainty has surrounded the launch date since senior NHS England officials urged caution over the readiness of IT systems. Despite this, […] The post Plans being ‘worked up’ in case Pharmacy First launch date is missed appeared first on The Pharmacist.
Outsourcing Pharma
DECEMBER 21, 2023
Decentralized clinical trials (DCTs) are gaining increasing interest as they have the potential to make clinical trial operations quicker, more efficient and more accessible to patients. Check out five DCT organizations that have raised big venture capital investments in the last few years.
pharmaphorum
DECEMBER 21, 2023
Servier has been found guilty of fraud and deception over weight loss therapy Mediator by French appeals court, and is fined €431 million
BioPharma Dive
DECEMBER 21, 2023
Ahead of a Phase 3 readout that could come next year, the pharma is paying $130 million in upfront and near-term cash for rights to the retinitis pigmentosa treatment that it didn’t already own.
Big Molecule Watch
DECEMBER 21, 2023
In the last month, there has been a flurry of activity at the PTAB related to challenges from biosimilar manufacturers related to ustekinumab, aflibercept, and eculizumab patents. 1. STELARA® (ustekinumab) Four months after Janssen Biotech, Inc. settled to terminate Samsung Bioepis Co., Ltd.’s inter partes review (IPR) challenge of U.S. Patent No. 10,961,307 (“the ’307 Patent”), directed to methods of treating ulcerative colitis with ustekinumab, Biocon Biologics Inc. has filed its own IPR chall
pharmaphorum
DECEMBER 21, 2023
Patient-centric advertising using zero-party data can provide effective and personalised healthcare marketing while ensuring compliance with legal regulations and industry standards.
Drug Patent Watch
DECEMBER 21, 2023
Annual Drug Patent Expirations for AUVI-Q Auvi-q is a drug marketed by Kaleo Inc and is included in one NDA. It is available from three suppliers. There are thirty-one patents… The post New patent for Kaleo Inc drug AUVI-Q appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
350 
Let's personalize your content